A configurable model of the synaptic proteome reveals the molecular mechanisms of disease co-morbidity.

Oksana Sorokina^{*1}, Colin Mclean^{*1}, Mike DR Croning², Katharina F Heil^{1,4}, Emilia Wysocka¹, Xin He⁵, David Sterratt¹, Seth GN Grant^{2,5}, T Ian Simpson^{1,5}, and J Douglas Armstrong^{1,3,5}.

Email: Colin Mclean* - Colin.D.Mclean@ed.ac.uk and Oksana Sorokina* - Oksana.Sorokina@ed.ac.uk

*Corresponding author

1. The School of Informatics, University of Edinburgh, Edinburgh, EH8 9AB, Scotland.

2. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom

3. Computational Biomedicine Institute (IAS-5 / INM-9), Forschungszentrum Jülich, Jülich, Germany

4. University of Barcelona, Barcelona, Spain

5. Simons Initiative for the Developing Brain

Abstract

Synapses contain highly complex proteomes which control synaptic transmission, cognition and behaviour. Genes encoding synaptic proteins are associated with neuronal disorders many of which show clinical co-morbidity. Our hypothesis is that there is mechanistic overlap that is emergent from the network properties of the molecular complex. To test this requires a detailed and comprehensive molecular network model.

We integrated 57 published synaptic proteomic datasets obtained between 2000 and 2019 that describe over 7000 proteins. The complexity of the postsynaptic proteome is reaching an asymptote with a core set of ~3000 proteins, with less data on the presynaptic terminal, where each new study reveals new components in its landscape. To complete the network, we added direct protein-protein interaction data and functional metadata including disease association.

The resulting amalgamated molecular interaction network model is embedded into a SQLite database. The database is highly flexible allowing the widest range of queries to derive custom network models based on meta-data including species, disease association, synaptic compartment, brain region, and method of extraction.

This network model enables us to perform in-depth analyses that dissect molecular pathways of multiple diseases revealing shared and unique protein components. We can clearly identify common and unique molecular profiles for co-morbid neurological disorders such as Schizophrenia and Bipolar Disorder and even disease comorbidities which span biological systems such as the intersection of Alzheimer's Disease with Hypertension.

Introduction.

At neuron-neuron synapses, the proteomes of presynaptic and postsynaptic compartments conduct neurotransmitter release and processing via complex and highly dynamic molecular networks. These signal transduction and plasticity processes underpin normal and abnormal information processing in the brain. The synaptic proteome is physically divided into pre- and postsynaptic subcellular compartments, where the postsynaptic proteome, often referred to as postsynaptic density or PSD, is believed to play a major role in processing and interpretation of the chemical messengers used in synaptic transmission between two neurons.

The PSD has been studied using high throughput proteomic methods for nearly 20 years. Initial smaller datasets (of order tens to hundreds) focused on interactomes associated with specific target proteins (NMDA receptors, AMPA receptors, PSD95, and other MAGUK proteins) [1-6]. Significant increases in the identified protein numbers (order of thousands) were achieved around 2010, when more advanced technologies were applied to whole post synaptic fractions (for example, [7-12]). To address potential noise in the sampling methods, a “consensus” PSD was proposed in 2004 [1] containing 466 proteins that had been reported in multiple studies to date and therefore were proposed as a higher confidence subset.

The pre-synaptic proteome mediates neurotransmitter release through the active zone, which organises the synaptic vesicle cycle through participation in vesicle loading, docking and priming, and calcium-triggering of fusion [13]. The history of the presynaptic proteome spans over 15 years, with the first descriptions in 2004, typically based on synaptic vesicle extraction and purification [14-18].

Proteins usually occur within supramolecular complexes and therefore proteomic datasets are often represented as static undirected protein-protein interaction (PPI) networks. Typically, the network vertices represent biomolecules, such as genes or proteins found in the studies. Edges represent the structural or protein interactions connecting them. Using such a network perspective we can exploit the many statistical measures and fundamental properties from the networks topology to gain insight and make predictions about the underlying data [19]. Vertex centrality

measures such as degree and betweenness reveal influential signalling proteins within the network. The 'scale-free' property [20] found in many biological networks can be used to identify hub genes, which often encode disease related genes [19]. Clustering algorithms attempt to identify densely connected communities (or modules) of vertices within the network [21, 22]. Synaptic gene-disease or gene-functional association data can then be annotated onto these communities and tests made for the functional/disease enrichment at the level of the cluster. This can be used to predict gene-sets associated with known synaptic diseases, which are useful elucidating molecular mechanisms[22]. Using this network approach, we can then test where these gene-sets overlap across different disorders.

Results.

1. Collating the synaptic proteome.

We systematically curated synaptic proteomic datasets from the literature, to produce a comprehensive index of the proteins (and their genes) reported at the synapse. To find proteomic studies we searched PubMed using the key words: “synaptic”, “postsynaptic”, “presynaptic”, “synaptosome”. Preference was given to the studies focussing on mammalian brains in healthy/normal experimental conditions. The many disease specific studies identified were not included. A total of 57 papers describing a landscape of 7814 synaptic genes (Table 1) were annotated with the following metadata: PUBMED ID, species, method of extraction, number of identified proteins and brain region. Each study’s respective protein list was extracted and mapped to stable identifiers (MGI, Entrez and Uniprot) for the predicted set of orthologues for three species (human, mouse, rat). Additional functional information (e.g. GO function, disease association) was overlaid as metadata onto the vertices. Supplementary Table 1 contains a detailed list of the papers found and associated metadata.

	PMID	GeneN	Brain region	Specie
Husi_2000	10862698	77	forebrain	mouse
Walikonis_2000	108118142	29	forebrain	rat
Peng_2004	15020595	237	forebrain	rat
Satoh_2002	11895482	45	forebrain	mouse
Youshimura_2004	14720225	436	forebrain	rat
Farr_2004	15447677	73	whole brain	rat
Jordan_2004	15169875	393	whole brain	mouse and rat
Li_2004	14532281	139	forebrain	rat
Trinidad_2005	15748150	236	whole brain	mouse
Cheng_2006	16507876	289	forebrain and cerebellum	rat
Collins_2006	16635246	620	forebrain	mouse
Dosemeci_2006	16332460	114	hippocampus	rat
Dosemeci_2007	17623647	276	cerebral cortex	rat
Trinidad_2008	18056256	2158	cortex, midbrain, cerebellum, and hippocampus	mouse
Selimi_2009	19402746	63	cerebellum	mouse
Fernandez_2009	19455133	301	forebrain	mouse
Bayes_2001	21170055	1443	cortex	human
Bayes_2012	23071613	1552	cortex	mouse
Schwenk_2013	22632720	34	whole brain	mouse
Distler_2014	25211037	3558	Hippocampus	mouse
Bayes_2014	25429717	1134	Frontal cortex	human
Frank_2015	2711747	145	forebrain	mouse
Uezu_2016	27609886	928	Cortex and hippocampus	mouse
Focking_2016	27898073	2021	Whole brain	human
Li_2016	27507650	1602	Hippocampus CA1	mouse
Fernandez_2017	29045836	107	forebrain	mouse
Roy_2017	29203896	1213	frontal, parietal, temporal and occipital lobes of the neocortex	human
Li_2017	28671696	993	Hippocampus CA1	mouse
Roy_2018	30071621	1071	frontal, medial and caudal cortex, right caudate putamen, right hippocampus, whole hypothalamus, and cerebellum (right half)	mouse
Wilson_2019	30986977	2134	cortex	mouse

Coughenour_2004	15378707	36	forebrain	rat
Blondeau_2004	15007177	209	Whole brain	rat
Phillips_2005	16047384	110	cortex	rat
Morciano_2005	16269012	153	Whole brain	rat
Burre_2006	17080482	165	Whole brain	rat
Takamori_2006	17110340	410	Cerebral cortex	rat
Khanna_2007	17562281	104	Whole brain	rat
Morciano_2009	19187093	369	Whole brain	rat
Abul-Husn_2009	19562802	138	Hippocampus and striatum	mouse
Abul-Husn_2011	22043286	145	striatum	rat
Gorini_2010	20114047	57	cortex	mouse
Gronborg_2010	20053882	618	Cerebral cortex	rat
Boyken_2013	23622064	414	Cerebral cortex	rat
Wilhelm_2014	24876496	1169	Cortex and cerebellum	rat
Brinkmalm_2014	24973420	68	Hippocampus	mouse
Weingarten_2014	24534009	482	Whole brain	mouse
Kokotos_2018	30301801	983	cerebellum	rat
Filiou_2010	20309889	2980	Whole brain	mouse
Dahlhaus_2011	21398567	673	Visual cortex	mouse
Cohen_2013	23658807	2668	cortex	rat
Biesemann_2014	24413018	163	forebrain	mouse
Chang_2015	25958317	2077	cortex	human
Liu_2014	25352669	1388	Hippocampus and prefrontal cortex	mouse
Distler_2014	25211037	4417	hippocampus	mouse
Kohansal-Nodehi_2016	27115346	4961	cerebellum	rat
Gonzalez-Lozano	27748445	1560	cortex	mouse
Alfieri_2017	28713243	351	telencephalon	mouse
Heo_2018	29610302	2272	Cortex and hippocampus	mouse

Table 1: Collection of 57 synaptic proteome studies at a glance. Postsynaptic studies are shown in blue, presynaptic in green and synaptosomal in yellow.

1.1 Post synaptic compartment.

We identified 30 major post synaptic proteome (PSP) studies published in a period spanning 2000-2019 that contribute a total of 5568 mouse and human unique gene identifiers (see Supplementary Table 1). Most of these PSP datasets were obtained by proteomic analysis of biochemical fractions of synaptosomes obtained from homogenised brain samples [3-12, 23-28].

Further studies were added that focussed on specific protein complexes using immune, peptide, transgenic affinity purification or in vivo affinity purification approach strategies against well-known PSD proteins, e.g. mGluR5 [29], PSD-95 [2, 25, 26, 30], NMDA [1, 2, 31] and AMPA receptors complex [2, 32] or gephyrin [30].

The majority of PSP samples were collected from whole brain [3, 10, 29, 32, 33] and forebrain [1, 2, 4-6, 23, 27, 34, 35]. However, several studies focus on specific brain regions, e.g hippocampus [12, 24, 36, 37] and cerebellum [23, 25]. Several studies that considered multiple distinct brain regions simultaneously were also included [11, 38, 39].

The discovery rate of new PSD proteins was analysed across the multiple studies as shown in Figure 1A, where the number of proteins is plotted against the frequency of identification. Figure 1B shows the ratio of newly identified proteins (black) per year compared to the total number of PSP proteins identified in that year (blue). Two major jumps in the gross number of proteins identified occur in 2008, when 1249 new proteins were reported by [11] and in 2014 with 2588 new proteins added by [12].

The most frequently found proteins (i.e. detected in 22, or more, studies out of the 29) include very well-known PSD proteins, for example: DLG4 (found 28/29), CAMK2A (27/29), INA (26/29), SPTBN1, CAMK2B, DLG2, NSF, GRIN2B, GRIN1 (25/29), BIAP2, BSN (24/29) (full list in Supplementary Table 2).

High throughput proteomic techniques are powerful, but they are noisy, and contamination is always a concern. A large number (2091) of PSP proteins have been observed just once. While single hits may be accounted for by lack of sensitivity with low abundance molecules, it could also indicate the presence of false positive components brought in by experimental uncertainty.

The rate of growth with respect to newly discovered proteins appears to be slowing (Figure 1B) and therefore there is now an opportunity to define a more reliable subset. Following the approach described in [1], we selected genes found in two or more independent studies to designate the “consensus” PSP. This resulted in 3441 genes, which is ~7 times larger than reported by [1] and describes a subset of synaptic proteins for which have higher confidence. In this subset we observe the increment of new genes per year decreases after 2008 and drops completely after 2014 (Figure 1C). Seeing that the accumulated number of consensus PSP genes is plateauing, we performed a non-linear fit to extrapolate a predicted total number of consensus PSP genes (Figure 1F, Methods). From the fit, we predict a total number of consensus PSP genes to be 3499 ($P = 2.36E-11$, residual standard error: 192.7 on 12 degrees of freedom) (Figure 1F) by year 2023 which, when compared to the current number (3438) indicates that our knowledge on PSP components, based on currently available methodologies, is close to saturation.

Figure 1. Accumulation of the unique synaptic genes by year. A. Frequency of protein identification in 29 PSP studies. B. Cumulation of the new PSP genes (black) compared to the total datasets (blue) over years. C. Accumulation of new “consensus” PSP genes (black) compared to the total datasets (blue) over years. D. Frequency of protein identification in 17 presynaptic studies. E. Accumulation of new presynaptic genes (black) compared to the total datasets (blue) over years. F. Non-linear fit to predict the total size of “consensus” PSP (3499 genes) ($P = 2.36E-11$). G. Overlap of three synaptic datasets: presynaptic, postsynaptic and synaptosomal.

1.2 Presynaptic compartment.

For the presynaptic compartment we identified 17 published studies spanning a period from 2004 to 2018, which contribute to 2315 unique human and mouse gene IDs (Supplementary Table 1). As with the PSP studies, presynaptic studies can be methodologically sorted into shotgun and target specific approaches. Shotgun approaches include the majority of studies (14/17), which span differing fractions of presynaptic compartment. This includes studies of the entire presynaptic nerve terminal and plasma membrane [16, 40, 41] to more specific studies of clathrin coated vesicles (CCV) [42], presynaptic particle fraction (PPF) [43], synaptic vesicles (SVs) [14-18, 44-47], and activity -dependent bulk endocytosis (ADBE) [48]. The three remaining studies consider target protein complexes obtained by Co-IP for N-type calcium channels (CaV2.2/CACNA1B) [49], SNAP -25 [50, 51], BKCa, dynamin-1, SNAP-25, syntaxin-1A, and VAMP-2 [51]. Presynaptic studies span a variety of anatomical regions from whole brain [15-18, 42, 49] to subregion specific, such as cortex [14, 43, 45-47, 51], hippocampus [40, 50] and striatum [40, 41].

The frequency of identification of the presynaptic proteins is shown in Figure 1D. From Figure 1E, we see two jumps in newly discovered proteins correspond to studies performed in years 2010 and 2014. Approximately half of the proteins in the presynaptic proteome (1064 genes) have been reported more than twice, which can be viewed as a rough estimate for the consensus of presynapse, however the recent trend in newly identified genes indicates that saturation has not been achieved yet (see Methods). The most frequent presynaptic genes found in the majority of the studies include AP2B1, HSPA8, GNAO1, ACTB (15/17), STX1B, ATP6V0A1, STXBP1, ATP1A3, ATP6V1E1, SYT1, GNB1, TUBA1A, VAMP2, NSF, DNMT1 (14/17) with full statistics available in Supplementary Table 3.

1.3 Synaptosome.

Although most studies targeted pre or post synaptic regions specifically we also considered 11 studies that span the whole synaptosome and reported 6888 unique

genes. These cover most but not all of the genes/proteins reported in the focussed studies (Figure 1G). In summary, 599 of specifically postsynaptic, 250 of published specifically presynaptic and 35 of their joint overlap were not detected in global synaptosome studies. Supplementary Table 4 contains the whole list of 7814 unique synaptic genes classified according their localisation (presynaptic, post synaptic, synaptosomal) based on the 57 studies considered here.

As before, most of the studies (9/11) could be classified as shotgun proteomic experiments where the entire synaptosome is analysed for its molecular components [12, 52-58]. Two studies describe the molecular structure of specific protein complexes by Co-IP targeting of kinesin (Kif5C and Kif3A) [59] and P140Cap (SRCIN1) [60]. In terms of brain region origin of the sample, the majority of the studies consider hippocampus [12, 55, 58, 59]; visual cortex [53], motor cortex [56], prefrontal cortex [59] and, cerebral cortex [61].

2. Reconstructing molecular interaction networks.

To reconstruct protein-protein interaction (PPI) networks for the pre- and post-synaptic proteomes we used human PPI data obtained from three databases: BioGRID [62], Intact [63] and DIP [64]. These data were filtered for the highest confidence direct and physical interactions (see Methods; Table 2), for which we excluded all predicted interactions and those obtained from Co-IP experiments. The resulting PSP network contains 4,817 nodes and 27,788 edges in the Largest Connected Component (LCC). The presynaptic network is significantly smaller and comprises 1780 nodes and 6620 edges in the LCC.

Total N of unique Human PPIs extracted from three databases	N of unique Human PPIs after filtering for direct/physical interaction	N of unique PPIs in PSP network	N of unique PPIs in PSP "consensus" network	N of unique PPIs in Presynaptic network
407,643	126,579	28,915	14,496	6,625

Table 2. Summary of protein-protein interactions (PPIs) in this study. PPI numbers before and after filtering for direct and physical interactions (Methods)

3. Using the Synaptic Proteome Model.

We captured the original heterogeneity of the datasets by incorporating the necessary metadata so that they can be used in queries that retrieve specific subsets of interest, e.g. only human, only presynaptic, or, say, only genes obtained in Co-IP experiments from hippocampus. To make the datasets readily accessible based on custom selection criteria we embedded them in a SQLite relational database.

In addition to the proteomic, interactomic data and metadata mentioned above, the database also includes the GO function information for three species: mouse, rat and human, disease annotation for human (based on Human Disease Ontology (HDO)[65]) and GeneToModel table, which links certain synaptic proteins to existing computational models of synaptic plasticity and synaptic signal transduction (*Sterratt in preparation*). The database structure is shown at Figure 2 and described in detail in respective Methods section.

Figure 2. Entity Relationship diagram for the SQLite database of the synaptic proteome.

We provide the data as simple flat tables for maximum flexibility and a SQLite implementation. For anyone who wishes to explore the data we also provide a simple walkthrough of how to install the system and run the following common uses/queries from SQLite Studio or R (Supplementary Files). Following use cases illustrate how the database can be used to obtain the information for specific protein(s) and build the PPI network for subset of proteins (1,2), and how the PPI network can be used for further analysis (3,4).

Database is available from Supplementary Data.

3.1. Finding information for specific gene/s of interest.

Among the common questions in the neuroscientific community are “What is known about my favourite gene/protein? Is it pre- or postsynaptic? Which brain region it was found and by whom?”. Evidence to address these types of questions can be extracted by simple database queries using protein name (gene name) or gene Entrez ID. For example, to find the information for protein “SRCIN1”, the query will look like:

```
SELECT Localisation,
        HumanEntrez,
        HumanName,
        PaperPMID,
        Paper,
        YEAR,
        BrainRegion
FROM FullGeneFullPaperFullRegion
WHERE HumanName = "SRCIN1"
```

Here, FullGeneFullPaperFullRegion is a database view that combines the major information for all genes in more convenient spreadsheet style representation.

The database returns the results in a form of table (Table 3 contains top 17 rows), showing that SRCIN1 was found in 25 postsynaptic, 7 presynaptic and 12 synaptosomal studies, along with brain regions where it was reported.

Table 3 A snippet of available information for SRCIN1

Compartment	EntrezID	GeneName	PMID	AUTHOR_YEAR	Brain region
Postsynaptic	80725	SRCIN1	15447677	FARR_2004	Brain
Postsynaptic	80725	SRCIN1	15020595	PENG_2002	Forebrain
Postsynaptic	80725	SRCIN1	18056256	TRINIDAD_2008	Midbrain
Postsynaptic	80725	SRCIN1	18056256	TRINIDAD_2008	Cerebellum
Postsynaptic	80725	SRCIN1	30071621	ROY_2018	Hypothalamus
Postsynaptic	80725	SRCIN1	16332460	DOSEMESI_2006	Hippocampus
Postsynaptic	80725	SRCIN1	30071621	ROY_2018	Striatum
Postsynaptic	80725	SRCIN1	17623647	DOSEMESI_2007	Cerebral cortex
Postsynaptic	80725	SRCIN1	29203896	ROY_2017	Frontal lobe
Presynaptic	80725	SRCIN1	24876496	WILHELM_2014	Cerebellum
Presynaptic	80725	SRCIN1	17110340	TAKAMORI_2006	Cerebral cortex
Synaptosome	80725	SRCIN1	27115346	KOHANSAL_NODEHI_2016	Cerebellum
Synaptosome	80725	SRCIN1	28713243	ALFIERI_2017	Telencephalon
Synaptosome	80725	SRCIN1	25211037	DISTLER_2014	Hippocampus
Synaptosome	80725	SRCIN1	27115346	KOHANSAL_NODEHI_2016	Cerebral cortex
Synaptosome	80725	SRCIN1	25352669	LIU_2014	Prefrontal cortex
Synaptosome	80725	SRCIN1	25958317	CHANG_2015	Motor cortex
Synaptosome	80725	SRCIN1	21398567	DAHIHAUS_2011	Visual cortex

3.2. Building a custom PPI network from a protein list.

We can easily extract a customised subset of the PPI network that includes specific studies, brain regions or compartments. The example query for a presynaptic protein list and its respective PPI network is as follows:

```

SELECT DISTINCT A,
                B
FROM PPI
JOIN FullGeneFullPaper f1 ON f1. GeneID= A
JOIN FullGeneFullPaper f2 ON f2. GeneID =B

```

```
WHERE f1. Localisation= 'Presynaptic'
AND f2. Localisation ='Presynaptic'
```

This will result in a list of protein interaction pairs of type “Human_Entrez_ID_A - - Human_EntrezID_B”, which can be visualised in R, using package *Igraph* (<https://igraph.org/redirect.html>), loaded to Cytoscape via *RCy3* package [66] or saved as csv file and analysed with Cytoscape (<https://cytoscape.org/>) or Gephi (<https://gephi.org/>).

3.3. Measuring how network topology correlates with functional/disease importance: Bridgeness.

The relative importance of specific proteins to propagate information (i.e. signals) through a network can be estimated from the position of the protein within the network's architecture and its substructures. The number of proteins interacting neighbours (degree) is considered as important property as it may reflect protein importance for signal propagation in the network. This can be extended to include local interacting partners, a measure known as Semi-local centrality [67].

Clustering is commonly used to identify substructures/communities within networks. Concrete clustering methods usually assign each protein to the single most likely community despite many of them actually being involved in multiple communities. To match this we calculate the probability of each protein being involved in every cluster in the network. The more communities a specific protein “bridges” (has a probability belonging to) the more likely it is involved in communicating between these communities across the network [68] (Methods). We hypothesise these 'Bridging' proteins will also correlate with functional/disease importance at the biological level.

Figure 3. Bridging proteins estimated using the Spectral clustering algorithm. Bridgeness is plotted against semi-local centrality (Methods), allowing categorisation of the proteins to three important groups: Region 1, proteins that are likely to have a 'global' rather than 'local' influence in the network (also been called bottle-neck bridges [69], connector or kinless hubs [70] lie in the range (DLG4, GRIN2B, CAMK2A, etc). Region 2, proteins likely to have an influential 'globally' and 'locally' in the network (EGFR, HRAS, NRAS, etc). Region 3, more likely to be centred within the community they're found in, but

also focused on communicating with a few other specific communities (GRIN1, GRIA2-4), "secondary bridging proteins". Region 4, proteins whose impact is mostly 'locally', primarily within one or two communities (local hubs [68]).

Using the Spectral clustering algorithm [71], we estimated the Bridgeness for the PSP network and identified a total of 3884 (3884/4817 ~ 80%) proteins with Bridgeness value more than 0.1.

We then plotted Bridgeness against Semi-local centrality values (see Methods) to categorise the proteins by their ability to influence the network globally and locally (Figure 3, Supplementary Table 5). Region 1 contains 1126 proteins (see Region 1 in Figure 3, Supplementary table 5), which, between them affect many (i.e. greater than half) communities in the network yet each is relatively localised in the network (low local-centrality values) – we call these “bridging” or “influential”. Of those 1126 - 28 are considered as core PSD95/DLG4 interactors [34] (28/77 ~36%) within the postsynaptic proteome including: DLG4, GRIN2A, GRIN2B, CAMK2A, CALM1, NSF. Interestingly, we found NMDA-receptor subunits proteins GRIN1 and AMPA-receptor subunit proteins (GRIA2,3,4) clustered together as secondary Bridging proteins (see Region 3 in Figure 3), indicating their influence on a small number of selected functional clusters. There are a few scaffold proteins which bind to the AMPA-receptor subunits which are Bridging Proteins, e.g. DLG1, PICK1, GRIP1.

Among 1126 Bridging proteins, 512 (512/1126 ~45%) were found associated with at least one synopathies given in our set (Methods), 248 (214/1126 ~ 19%) with multiple diseases including: APP (AD&Epi&ASD&PD&HTN&MS&FTD), VDAC1 (AD&PD&MS), and MAPK14 (AD&SCH&HD&HTN&MS). Indeed, using the Spectral algorithm we found significant overlaps between the Bridging proteins (see Region 1 in Figure 3) and disease association; AD ($P=7.74E-10$,***), HTN ($P=1.16E-07$ ***), HD ($P=8.01E-7$ ***), PD ($P=7.9E-5$ ***). Moreover, when we considered synaptic function (GO annotation), we found a significant overlap for AD with innate immune response-activating signal transduction (GO:0002758, AD= 4.3×10^{-11} , HTN= 9.7×10^{-10}), stress-activated MAPK cascade (GO:0051403, AD= 3.3×10^{-12} , HTN= 4.3×10^{-11}) and calcium-mediated signaling (GO:0019722, AD= 1.1×10^{-3}).

3.4. Extracting and comparing shared disease pathways.

Given gene-disease annotation (GDA) data and the PPI network topology, we can start to dissect how these different neurological diseases might coalesce at the synapse. The methodology described in [72] tests the extent to which two diseases might share a common molecular mechanism. Briefly, within the network we calculate z-scores from the observed mean shortest distance between disease GDA's, relative to 10000 random permutation of each diseases GDA's, to quantify the disease pairs overlap (Methods). From the set of p-values, calculated from these z-scores, we then correct for false positives by calculating the q-values (Supplementary Table 6).

Figure 4 shows the comparison of the disease pair overlaps obtained for common neurological and neurodevelopmental diseases and disorders in pre- and post-synaptic networks. It can be seen that the overlap for common neuro-psychiatric/developmental disorders was observed in both postsynaptic and presynaptic PPI network models (post/pre), however q-values are smaller for presynaptic network, probably due to its size: BP-ASD ($P=8.79E-14/1.44E-03$), BP-SCH ($P=2.65E-25/9.55E-11$), ASD/SCH ($P=8.74E-07/9.82E-03$). Similarly, overlap was observed for common neurodegenerative diseases/conditions AD and PD ($P=1.74E-5/1.92E-05$).

463

464

465 Hypertension (HTN) is considered one of the leading vascular risk factors associated

466 with neurological diseases/disorders including AD, PD and FTD [73-75], and BD and

467 SCH [76, 77]. With the PSP PPI network model, we found a strong overlap for HTN

468 with AD ($P=8.6E-4$, and with MS ($P=8.79E-5$), but not with the other

469 neurodegenerative diseases: FTD-HTN, PD-HTN, Epi-HTN and HD-HTN which all

470 have q -values > 0.05 (Supplementary Table 6). When considering the set of common

471 neuro-psychiatric/ developmental disorders with HTN, we found all four overlap with

472 HTN, i.e., but that there was no evidence these overlaps were significant when

473 considering a full randomised model: HTN-SCH ($P=0.9$), HTN-BD ($P=0.9$), HTN-ID

474 ($P=0.32$) and HTN-ASD ($P=1$).

475

476 The more a disease pair overlaps, the greater the evidence the corresponding disease

477 pair share the same genes, and therefore participate in similar pathways. Since we find

478 significant overlaps between AD-HTN and AD-PD, but not PD-HTN, it indicates a

potential shared mechanistic pathway between AD and HTN, which is different to the pathways shared between AD and PD; Supplementary Figure 3A and 3C illustrates this difference by plotting the z-score calculated against the distribution of for AD-HTN and PD-HTN after 10000 randomised models using the PSP network.

Discussion.

By systematic interrogation of the published literature we identified 57 studies that describe a molecular landscape of the synaptic proteome comprising 7617 unique mouse and human genes. Of this, the majority of the papers (29/57) are for the postsynaptic compartment, 17 are presynaptic and 11 consider the whole synaptosome. We combined all the datasets based on stable identifiers, which resulted in 5568 postsynaptic genes (3441 found in two or more studies forming an updated “consensus” PSP), 2315 presynaptic genes, and 6888 reported for synaptosome. We retrieved the PPIs for the list of genes, which allows us to build a comprehensive PPI map for the whole synapse or its subcellular compartments.

We embedded the datasets in a SQLite database to enable more flexible queries based on the species, brain region, method of identification or other metadata and allow the extraction of bespoke protein network models for subsequent analyses.

This dataset is the largest and the most complete up to date and is freely available with lightweight tools to allow anyone to extract relevant subsets. By mirroring the methods used it would be straightforward for any user to add in their own datasets for comparison.

The case studies described provide useful examples of the analyses that can be readily extracted from these data. In addition, to information for specific proteins, we can use the model to analyse the entire protein-protein interaction network to query topology-function relationships that provides insights for possible disease mechanism. For example, since the Bridging proteins are spread out over the network, the correlated disease-disease pairs we find are not centred in a single cluster but shared across several communities. In turn, the co-occurrence of enrichment of specific synaptic functions with disease in the discovered communities may indicate that molecular

complexes underlying the specific synaptic functions are also involved in disease mechanisms. When comparing across diseases we find evidence for shared molecular mechanisms that span common neurological disorders, such as Bipolar disease and Autism Spectrum Disorder, Bipolar Disease and Schizophrenia. Moreover we see evidence for molecular mechanisms that span more diverse disease pairs such as the existence of common molecular pathways linked to both Alzheimer's disease and Hypertension.

Methods.

1. Data cleaning and ID mapping

Synaptic studies for presynaptic, postsynaptic and whole synaptosome compartment were identified by manual curation of PubMed, starting from year 2000. Protein/gene lists from the published synaptic proteome studies were combined into the total list of synaptic components. Identifiers from each study were mapped to stable IDs including: Entrez Human and Mouse, Uniprot and MGI IDs. The resulting 'master list' contains only unique gene entries (rows) with corresponding studies (columns) where they have been identified. For example, if a protein was discovered in several studies all those respective columns will contain 1. A summary of all studies is presented in Supplementary Table 1. It contains the information for literature ID and some useful metadata such as species (mouse, human, rat), protein counts, brain region where the sample was taken from along with experimental methods used for protein identification and quantification.

2. Prediction of total size of pre- and postsynaptic proteome.

Only proteins that were found more than one time were taken into account to make the most confident "consensus" dataset for pre-and post-synaptic proteomes. We fitted the accumulation of new proteins against the year they were first time identified in R, using linear ($y \sim x$), and non-linear ($y \sim \text{SSlogis}(x, \text{Asym}, \text{xmid}, \text{scal})$) models. The goodness of fit was compared by Akaike's Information Criteria) AIC function [78], where lower indicates a more parsimonious model.

For post synaptic proteome the non-linear model is shown at Figure 1F and predicted maximum size of "consensus" PSP proteome is 3499, achieved by roughly 2023.

AIC coefficient is 213.8955 for linear fit and 205.0504 for non-linear fit, which means the latter is more parsimonious.

For presynaptic proteome the non-linear fit is shown at Supplementary Figure 1, predicting 1309 proteins in total reached by 2035 year. However, by AIC criteria, the linear model for presynaptic “consensus” proteome is better than non-linear (103.2001 and 107.2766, respectively), which likely means that presynaptic proteome is not in its “saturation” phase yet.

3. Protein-protein interaction data

Protein-Protein Interaction (PPI) dataset was assembled from three publicly available databases: DIP [62], IntAct [61] and BioGRID [60]. The interactions were retrieved in PSI-MITAB standard protein interaction format [74, 75]. The PSI-MITAB format enforces unified column contents and use of controlled vocabularies. These columns report different types of identifiers of an interactor pair, the PubMed identifier of publication where the interaction was reported, taxonomies of interactors, an interaction detection method, and an interaction type. The last two identifiers are defined with unique MI-terms specified in the Molecular Interactions Controlled Vocabulary (MI) ontology. The set of MI-terms representing each of the categories was obtained by parsing the MI ontology file (source: <https://www.ebi.ac.uk/ols/ontologies/mi>).

To limit the analysis to high-confidence direct physical interactions, those annotated by “association” term (MI:0914) and its offspring were preserved. This step excluded interactions of types: colocalization, functional association, genetic interaction and predicted interaction. Although MI ontology offers “direct interaction” term in the category of interaction type, according to the iMEX curation rules (https://github.com/IMEx-Consortium/IMEx-site/raw/gh-pages/static/files/imex_curation_rules.pdf) two hybrid assays are categorised as non-direct interactions. Therefore, this classification was not used to preserve interactions reported by two-hybrid assays. We further removed indirect interactions, often linked to methods likely to generate false positive hits (spoke-expansion). Interactions originating from experiments involving co-complexes (e.g. pull-down, affinity

technology) were excluded from the analysis by filtering out a selected subset of terms denoting these methods. Since the intAct interaction table indicates spoke-expanded interactions, these were also removed from the interaction set.

Integration of interaction tables required distinct parsing procedures per database, including translation into common interactor identifiers. DIP and IntAct databases use UniProtKB accessions (UniProtKB ACs) as their primary identifiers, e.g. P49418. On the other hand, BioGRID uses numeric Entrez Gene IDs, e.g. 1134. The unification of identifiers was achieved by combining mapping tables collected from NCBI and UniProtKB ftp servers (file addresses:

ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/idmapping/by_organism/RAT_10116_idmapping_selected.tab.gz

ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/idmapping/by_organism/HUMAN_9606_idmapping_selected.tab.gz

ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/idmapping/by_organism/MOUSE_10090_idmapping_selected.tab.gz

<ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2accession.gz>). Entrez Gene ID was chosen as a unifying identifier.

Interactors that were annotated with a different taxon than Mouse, Rat or Human were removed. Non-human Entrez Gene IDs were mapped to Human identifiers with gene orthology mapping tables available on NCBI ftp server (file address:

https://ftp.ncbi.nlm.nih.gov/gene/DATA/gene_orthologs.gz).

After application of the above criteria, 407 443 interactions were obtained.

Additionally, after manual curation, 200 interactions from PDB database were added directly to the PPI list with Method “MI:0114” – X-ray crystallography, and Type “MI:0407”- Direct interaction, which resulted in total of 407643 interactions.

All files where retrieved on the same date, 2020-06-18, parsed and integrated with a custom code available at https://gitlab.com/Wysocka/ppis_v02.

4. Estimation of Bridgeness and semi- local centrality measures.

To assess the topological importance of the proteins in PSP network we estimated two independent measures for each protein.

1) semi-local centrality $Cl(v)$, which takes into consideration both a vertex's degree, its nearest, and next to nearest neighbours:

$$Q(u) = \sum_{w \in I(u)} N(w)$$

$$Cl(v) = \sum_{u \in I(v)} Q(u)$$

- (1)

where $I(u)$ is the set of nearest neighbours of u and $N(w)$ is the number of nearest and next to nearest neighbours of the vertex w . We performed unity-based or feature scaling: $X - X_{min}/(X_{max}-X_{min})$ to normalise the semi-local centrality to lie in the range $[0,1]$.

Semi-local centrality differs from degree centrality therefore, in making use of more information, allowing us to also measure a vertices' spread' of information locally through the network.

2) Bridgeness $B(v)$ of vertex v to measure the influence of a gene due to the clustering [68] can be estimated as:

$$B(v) = 1 - \sqrt{\frac{c}{c-1} \left(\sum_{j=1}^c u_{jv} - \frac{1}{c} \right)^2} \quad -(2)$$

Where u_v is the community membership vector for vertex v , which is the probability of vertex v belonging to a given community $u_v = [u_{1v}, u_{2v}, \dots, u_{cv}]$,

where $\sum_j u_{jv} = 1$ and c is the number of communities detected by the algorithm.

The combination of these measures allows categorisation of the influence each has on the overall network structure (Figure 3):

5. Disease Network Localisation

We compared the gene-disease association for the pre and post-synaptic PPI networks using the combined OMIM/GeneRIF/Ensembl variation data for common set of synaptic diseases (or synaptopathies) [79]: Schizophrenia (SCH, DOID:5419), Autistic Spectrum Disorder (ASD, DOID:0060041), Autistic Disorder (AUT,

DOID:12849), Bipolar Disorder (BD, DOID:3312), Intellectual Disability (ID, DOID:1059), Alzheimer disease (AD, DOID:10652), Epilepsy Syndrome (Epi, DOID:1826), Parkinson's Disease (PD, DOID:14330), Frontotemporal Dementia (FTD, DOID:9255), Huntington's Disease (HD, DOID:12858), Multiple Sclerosis (MS, DOID:2377) and Hypertension (HTN, DOID:10763).

We investigated the overlap and separation of each disease-disease pair by measuring the mean shortest distance for each disease, using the shortest distance between each GDA to its next nearest GDA neighbour [72]. The overlap, or separation, of each disease-disease pair in the pre- post-synaptic PPI networks, could then be quantified using:

$$S_{AB} \equiv \langle d_{AB} \rangle - \frac{\langle d_{AA} \rangle + \langle d_{BB} \rangle}{2} \quad - (3)$$

Where $\langle d_{AA} \rangle$ and $\langle d_{BB} \rangle$ quantify the mean shortest network distance between genes associated with disease A (or B), and $\langle d_{AB} \rangle$ the mean shortest distance between diseases. S_{AB} is bound by the diameter of the network, i.e., $d_{max} \leq S_{AB} \leq d_{max}$ where d_{max} is 8, 7, 8 for the presynaptic, PSP and PSP consensus PPI networks respectively. The magnitude of S_{AB} depends on the number of GDSs associated with each disease. Large positive values imply two well separated diseases, while large negative values indicate large (number of GDAs) diseases with a big overlap, often implying one disease is the variant or precursor to the other. Each disease-disease network separation pair (S_{AB}) was compared against a full randomised model: drawing the same number of GDAs (from the set of all network genes) for each disease at random, before computing its separation. For each disease-disease pair, we performed 10,000 iterations of the full randomised model using the ECDF distributed computing facility.

The difference between the observed and randomised disease pair separations, was quantified using the z-score:

$$z - score_{AB} = \frac{S_{AB} - \langle S_{AB}^{rand} \rangle}{\sigma(S_{AB}^{rand})} \quad - (4)$$

Where $\langle S_{AB}^{rand} \rangle$ and (σ_{AB}^{rand}) are the mean and standard deviation obtained from the 10,000 iterations. Each disease-disease pair separation using the full randomised

model, i.e., S_{AB}^{rand} , was found to follow a normal distribution. We therefore assessed the significance of each disease-disease pair's separation, from P-values estimated from its z-score calculated in (4):

$$P - value(X = -|Z - score_{AB}|; \mu = 0, \sigma = 1) = [1 + erf\left(\frac{x-\mu}{\sigma\sqrt{2}}\right)]^{-1} \quad (5)$$

Where we take the negative of the absolute value of each disease-disease pairs z-score calculated in (4) and make use of R's *pnorm* function available in the 'stats' package (R version 3.4.2). The confidence in each disease-disease pairs P-value was tested for by calculating its q-value [80], and from the Bonferroni correction at the 0.05 (*), 0.01 (**) and 0.001 (***) significant levels.

5. SQL database

The database contains the following main tables:

- Gene: list of genes including IDs (MGI, Entrez Human and Mouse) and gene names (Human and Mouse).
- Specie: Tax ID (Human and Mouse)
- Paper: list of papers with PMID ID, name (in format "FirstAuthor_year"), year of publication
- Location: postsynaptic, presynaptic, synaptosome
- Method: shotgun or IP
- Brain region: list of regions where the samples originate, with hierarchical region structure
- PPI: human protein-protein interactions combined from BioGRID, Intact and DIP databases, contain information on methods, interaction type (PSI-MI nomenclature) and PMID info for each of the interactions.
- PaperGene: table links gene to respective papers and the metadata above
- GO: BP, CC and MF GO annotation for Human, Mouse and Rat species
- GOGene: gene to GO association list
- Disease: List of diseases from the HDO for Human
- DiseaseGene: genes to disease association list

- GeneToModel: genes with found association with published model of synaptic plasticity

The database is created with SQLite v 3.31.1 RDBMS in SQLite Studio v3.2.1.

Acknowledgements:

OS, CM, JDA, DS, were funded by European Union Horizon 2020 Specific Grant Agreement No. 72027 (Human Brain Project SGA2). OS and JDA were funded by European Union Horizon 2020 Specific Grant Agreement No. 945539 (Human Brain Project SGA3). The work of S.G.N.G. was supported by the UK Medical Research Council (G0802238, Defining the Human Synapse Proteome) and Simons Initiative for the Developing Brain. The Simons Initiative for the Developing Brain (SIDB) at the University of Edinburgh is supported by the Simons Foundation Autism Research Initiative (529085)

Author contribution:

OS, CM, MDC selected and curated the datasets; EW, KFH, XH, TIS designed and performed the PPI extraction and filtering; CM and OS performed the network analysis, wrote the analysis scripts and performed the statistical testing; OS constructed the SQLite database; OS, CM, JDA, DS, TIS, SGNG designed and directed the study, wrote and edited the manuscript.

Supplementary Figures and Tables.

Figure 1. Non-linear model for accumulation of presynaptic genes over years (year of first identification is considered), predicted number of 1309 genes, which should be reached by 2035.

Figure 2. The hierarchical structure of brain regions (human) existing in the database, according to 57 selected studies.

Figure 3. Linear mapping of Z-scores with ecd function used for assigning of gene compartment localisation.

Supplementary Table 1. List of 57 synaptic publications combined for the database with information on year, PUBMID, gene count, method, brain region and short description.

Supplementary Table 2. List of 5568 post synaptic genes collected from 29 publications listed as columns. 1 or 0 in each row corresponds to “found” or “not found” for each specific gene in each specific publication.

Supplementary Table 3. List of 2315 presynaptic genes collected from 17 publications listed as columns. 1 or 0 in each row corresponds to “found” or “not found” for each specific gene in each specific publication.

Supplementary Table 4. Full list of 7814 unique synaptic genes classified according their localisation (presynaptic, post synaptic, synaptosomal) based on 57 studies considered here. Localisation gets “1” if at least one publication has reported this gene for this compartment.

Supplementary Table 5. Estimation of Bridgeness values for PSP network protein.

Supplementary Table 6. Estimation of disease pairs overlap.

References.

1. Collins, M.O., et al., *Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome*. J Neurochem, 2006. **97 Suppl 1**: p. 16-23.
2. Husi, H., et al., *Proteomic analysis of NMDA receptor-adhesion protein signaling complexes*. Nat Neurosci, 2000. **3**(7): p. 661-9.
3. Jordan, B.A., et al., *Identification and verification of novel rodent postsynaptic density proteins*. Mol Cell Proteomics, 2004. **3**(9): p. 857-71.
4. Li, K.W., et al., *Proteomics analysis of rat brain postsynaptic density. Implications of the diverse protein functional groups for the integration of synaptic physiology*. J Biol Chem, 2004. **279**(2): p. 987-1002.
5. Peng, J., et al., *Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry*. J Biol Chem, 2004. **279**(20): p. 21003-11.
6. Yoshimura, Y., et al., *Molecular constituents of the postsynaptic density fraction revealed by proteomic analysis using multidimensional liquid chromatography-tandem mass spectrometry*. J Neurochem, 2004. **88**(3): p. 759-68.
7. Bayes, A., et al., *Comparative study of human and mouse postsynaptic proteomes finds high compositional conservation and abundance differences for key synaptic proteins*. PLoS One, 2012. **7**(10): p. e46683.
8. Bayes, A., et al., *Characterization of the proteome, diseases and evolution of the human postsynaptic density*. Nat Neurosci, 2011. **14**(1): p. 19-21.
9. Bayes, A., et al., *Human post-mortem synapse proteome integrity screening for proteomic studies of postsynaptic complexes*. Mol Brain, 2014. **7**: p. 88.
10. Trinidad, J.C., et al., *Phosphorylation state of postsynaptic density proteins*. J Neurochem, 2005. **92**(6): p. 1306-16.
11. Trinidad, J.C., et al., *Quantitative analysis of synaptic phosphorylation and protein expression*. Mol Cell Proteomics, 2008. **7**(4): p. 684-96.
12. Distler, U., et al., *In-depth protein profiling of the postsynaptic density from mouse hippocampus using data-independent acquisition proteomics*. Proteomics, 2014. **14**(21-22): p. 2607-13.
13. Chua, J.J., et al., *The architecture of an excitatory synapse*. J Cell Sci, 2010. **123**(Pt 6): p. 819-23.
14. Boyken, J., et al., *Molecular profiling of synaptic vesicle docking sites reveals novel proteins but few differences between glutamatergic and GABAergic synapses*. Neuron, 2013. **78**(2): p. 285-97.
15. Burre, J., et al., *Analysis of the synaptic vesicle proteome using three gel-based protein separation techniques*. Proteomics, 2006. **6**(23): p. 6250-62.
16. Morciano, M., et al., *Immunoisolation of two synaptic vesicle pools from synaptosomes: a proteomics analysis*. J Neurochem, 2005. **95**(6): p. 1732-45.
17. Morciano, M., et al., *The proteome of the presynaptic active zone: from docked synaptic vesicles to adhesion molecules and maxi-channels*. J Neurochem, 2009. **108**(3): p. 662-75.
18. Weingarten, J., et al., *The proteome of the presynaptic active zone from mouse brain*. Mol Cell Neurosci, 2014. **59**: p. 106-18.
19. Vidal, M., M.E. Cusick, and A.L. Barabasi, *Interactome networks and human disease*. Cell, 2011. **144**(6): p. 986-98.
20. Barabasi, A.L. and R. Albert, *Emergence of scaling in random networks*. Science, 1999. **286**(5439): p. 509-12.

21. Newman, M.E., *Modularity and community structure in networks*. Proc Natl Acad Sci U S A, 2006. **103**(23): p. 8577-82.
22. Pocklington, A.J., J.D. Armstrong, and S.G. Grant, *Organization of brain complexity--synapse proteome form and function*. Brief Funct Genomic Proteomic, 2006. **5**(1): p. 66-73.
23. Cheng, D., et al., *Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum*. Mol Cell Proteomics, 2006. **5**(6): p. 1158-70.
24. Dosemeci, A., et al., *Preparation of postsynaptic density fraction from hippocampal slices and proteomic analysis*. Biochem Biophys Res Commun, 2006. **339**(2): p. 687-94.
25. Dosemeci, A., et al., *Composition of the synaptic PSD-95 complex*. Mol Cell Proteomics, 2007. **6**(10): p. 1749-60.
26. Fernandez, E., et al., *Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins*. Mol Syst Biol, 2009. **5**: p. 269.
27. Satoh, K., et al., *Identification of activity-regulated proteins in the postsynaptic density fraction*. Genes Cells, 2002. **7**(2): p. 187-97.
28. Selimi, F., et al., *Proteomic studies of a single CNS synapse type: the parallel fiber/purkinje cell synapse*. PLoS Biol, 2009. **7**(4): p. e83.
29. Farr, C.D., et al., *Proteomic analysis of native metabotropic glutamate receptor 5 protein complexes reveals novel molecular constituents*. J Neurochem, 2004. **91**(2): p. 438-50.
30. Uezu, A., et al., *Identification of an elaborate complex mediating postsynaptic inhibition*. Science, 2016. **353**(6304): p. 1123-9.
31. Frank, R.A., et al., *NMDA receptors are selectively partitioned into complexes and supercomplexes during synapse maturation*. Nat Commun, 2016. **7**: p. 11264.
32. Schwenk, J., et al., *High-resolution proteomics unravel architecture and molecular diversity of native AMPA receptor complexes*. Neuron, 2012. **74**(4): p. 621-33.
33. Focking, M., et al., *Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder*. Transl Psychiatry, 2016. **6**(11): p. e959.
34. Fernandez, E., et al., *Arc Requires PSD95 for Assembly into Postsynaptic Complexes Involved with Neural Dysfunction and Intelligence*. Cell Rep, 2017. **21**(3): p. 679-691.
35. Walikonis, R.S., et al., *Identification of proteins in the postsynaptic density fraction by mass spectrometry*. J Neurosci, 2000. **20**(11): p. 4069-80.
36. Li, J., et al., *Long-term potentiation modulates synaptic phosphorylation networks and reshapes the structure of the postsynaptic interactome*. Sci Signal, 2016. **9**(440): p. rs8.
37. Li, J., et al., *Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders*. Nat Neurosci, 2017. **20**(8): p. 1150-1161.
38. Roy, M., et al., *Regional Diversity in the Postsynaptic Proteome of the Mouse Brain*. Proteomes, 2018. **6**(3).
39. Roy, M., et al., *Proteomic analysis of postsynaptic proteins in regions of the human neocortex*. Nat Neurosci, 2018. **21**(1): p. 130-138.
40. Abul-Husn, N.S., et al., *Systems approach to explore components and interactions in the presynapse*. Proteomics, 2009. **9**(12): p. 3303-15.

41. Abul-Husn, N.S., et al., *Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis*. PLoS One, 2011. **6**(10): p. e25535.
42. Blondeau, F., et al., *Tandem MS analysis of brain clathrin-coated vesicles reveals their critical involvement in synaptic vesicle recycling*. Proc Natl Acad Sci U S A, 2004. **101**(11): p. 3833-8.
43. Phillips, G.R., et al., *Proteomic comparison of two fractions derived from the transsynaptic scaffold*. J Neurosci Res, 2005. **81**(6): p. 762-75.
44. Coughenour, H.D., R.S. Spaulding, and C.M. Thompson, *The synaptic vesicle proteome: a comparative study in membrane protein identification*. Proteomics, 2004. **4**(10): p. 3141-55.
45. Gronborg, M., et al., *Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein*. J Neurosci, 2010. **30**(1): p. 2-12.
46. Takamori, S., et al., *Molecular anatomy of a trafficking organelle*. Cell, 2006. **127**(4): p. 831-46.
47. Wilhelm, B.G., et al., *Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins*. Science, 2014. **344**(6187): p. 1023-8.
48. Kokotos, A.C., et al., *Activity-dependent bulk endocytosis proteome reveals a key presynaptic role for the monomeric GTPase Rab11*. Proc Natl Acad Sci U S A, 2018. **115**(43): p. E10177-e10186.
49. Khanna, R., A. Zougman, and E.F. Stanley, *A proteomic screen for presynaptic terminal N-type calcium channel (CaV2.2) binding partners*. J Biochem Mol Biol, 2007. **40**(3): p. 302-14.
50. Brinkmalm, A., et al., *Targeting synaptic pathology with a novel affinity mass spectrometry approach*. Mol Cell Proteomics, 2014. **13**(10): p. 2584-92.
51. Gorini, G., et al., *Dynamin-1 co-associates with native mouse brain BKCa channels: proteomics analysis of synaptic protein complexes*. FEBS Lett, 2010. **584**(5): p. 845-51.
52. Filiou, M.D., et al., *Profiling of mouse synaptosome proteome and phosphoproteome by IEF*. Electrophoresis, 2010. **31**(8): p. 1294-301.
53. Dahlhaus, M., et al., *The synaptic proteome during development and plasticity of the mouse visual cortex*. Mol Cell Proteomics, 2011. **10**(5): p. M110.005413.
54. Cohen, L.D., et al., *Metabolic turnover of synaptic proteins: kinetics, interdependencies and implications for synaptic maintenance*. PLoS One, 2013. **8**(5): p. e63191.
55. Biesemann, C., et al., *Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting*. Embo j, 2014. **33**(2): p. 157-70.
56. Chang, R.Y., et al., *SWATH analysis of the synaptic proteome in Alzheimer's disease*. Neurochem Int, 2015. **87**: p. 1-12.
57. Gonzalez-Lozano, M.A., et al., *Dynamics of the mouse brain cortical synaptic proteome during postnatal brain development*. Sci Rep, 2016. **6**: p. 35456.
58. Heo, S., et al., *Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover*. Proc Natl Acad Sci U S A, 2018. **115**(16): p. E3827-e3836.
59. Liu, X.A., et al., *New approach to capture and characterize synaptic proteome*. Proc Natl Acad Sci U S A, 2014. **111**(45): p. 16154-9.

60. Alfieri, A., et al., *Synaptic Interactome Mining Reveals p140Cap as a New Hub for PSD Proteins Involved in Psychiatric and Neurological Disorders*. Front Mol Neurosci, 2017. **10**: p. 212.
61. Kohansal-Nodehi, M., et al., *Analysis of protein phosphorylation in nerve terminal reveals extensive changes in active zone proteins upon exocytosis*. Elife, 2016. **5**.
62. Oughtred, R., et al., *The BioGRID interaction database: 2019 update*. Nucleic Acids Res, 2019. **47**(D1): p. D529-d541.
63. Kerrien, S., et al., *The IntAct molecular interaction database in 2012*. Nucleic Acids Res, 2012. **40**(Database issue): p. D841-6.
64. Salwinski, L., et al., *The Database of Interacting Proteins: 2004 update*. Nucleic Acids Res, 2004. **32**(Database issue): p. D449-51.
65. Schriml, L.M., et al., *Human Disease Ontology 2018 update: classification, content and workflow expansion*. Nucleic Acids Res, 2019. **47**(D1): p. D955-d962.
66. Gustavsen, J.A., et al., *RCy3: Network biology using Cytoscape from within R*. F1000Res, 2019. **8**: p. 1774.
67. Kang, W., et al., *Identifying influential nodes in complex network based on weighted semi-local centrality*, in *2016 2nd IEEE International Conference on Computer and Communications (ICCC)*. 2016, IEEE: Chengdu, China.
68. Nepusz, T., H. Yu, and A. Paccanaro, *Detecting overlapping protein complexes in protein-protein interaction networks*. Nat Methods, 2012. **9**(5): p. 471-2.
69. Najafi, M., et al., *Overlapping communities reveal rich structure in large-scale brain networks during rest and task conditions*. Neuroimage, 2016. **135**: p. 92-106.
70. Guimerà, R. and L.A. Nunes Amaral, *Functional cartography of complex metabolic networks*. Nature, 2005. **433**(7028): p. 895-900.
71. McLean, C., et al., *Improved Functional Enrichment Analysis of Biological Networks using Scalable Modularity Based Clustering*. Journal of Proteomics and Bioinformatics, 2016. **9**(1): p. 9-18.
72. Menche, J., et al., *Disease networks. Uncovering disease-disease relationships through the incomplete interactome*. Science, 2015. **347**(6224): p. 1257601.
73. Raz, L., J. Knoefel, and K. Bhaskar, *The neuropathology and cerebrovascular mechanisms of dementia*. J Cereb Blood Flow Metab, 2016. **36**(1): p. 172-86.
74. Hou, L., et al., *Hypertension and Diagnosis of Parkinson's Disease: A Meta-Analysis of Cohort Studies*. Front Neurol, 2018. **9**: p. 162.
75. McGrath, E.R., et al., *Blood pressure from mid- to late life and risk of incident dementia*. Neurology, 2017. **89**(24): p. 2447-2454.
76. Amare, A.T., et al., *The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies*. Transl Psychiatry, 2017. **7**(1): p. e1007.
77. Gouvea, E.S., et al., *Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis*. Transl Psychiatry, 2016. **6**(10): p. e908.
78. Seo, T.K. and J.L. Thorne, *Information Criteria for Comparing Partition Schemes*. Syst Biol, 2018. **67**(4): p. 616-632.
79. Grant, S.G., *Synaptopathies: diseases of the synaptome*. Curr Opin Neurobiol, 2012. **22**(3): p. 522-9.
80. Storey, J.D. and R. Tibshirani, *Statistical significance for genomewide studies*. Proc Natl Acad Sci U S A, 2003. **100**(16): p. 9440-5.